In patients with AD, we did observe a trend in downregulation of IL-1α, COX2, OX40, CXCL13 and IL27RA, further supporting that the inflammation in AD is pleiotropic and that IRAK4 targeting may be capable of modifying the disease by impacting novel pathways. This evidence concerns the gene PTGS2 and Alzheimer disease.